Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265952 · ClinicalTrials.gov registry record · Phase 2
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02265952: Completed Phase 2 study, sponsored by Regeneron Pharmaceuticals.
NCT02265952 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02265952, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is an open-label, single-arm study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia (HoFH).
Primary Outcome
Percent change was reported for low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) up to week 4. LDL-C was measured using conventional units mg/dL. The efficacy analysis set included all participants in the safety analysis set (SAF) who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.
Interventions
- DRUG REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02-04 |
| Est. Completion | 2018-07-23 |
| Phase | Phase 2 |
What the finished NCT02265952 record still lists
NCT02265952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which REGN1500 250 mg SC/15 mg/kg IV/450 mg SC is the first listed.
NCT02265952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02265952 about?
NCT02265952 is a clinical study titled "Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". This is an open-label, single-arm study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia (HoFH).
What is the current status of trial NCT02265952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-02-04. Estimated completion is 2018-07-23.
What interventions are being tested in trial NCT02265952?
The interventions under investigation include: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC (DRUG).
Who is sponsoring clinical trial NCT02265952?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02265952's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI